Royston, UK (22nd November 2011) – Microfluidics expert,
Dolomite, is delighted to announce its collaboration with Clearbridge BioMedics
in the development of a novel instrument capable of detecting and isolating
Circulating Tumour Cells (CTCs) from small quantities of whole, unprocessed blood.
The innovative ClearCell™ System can isolate, enumerate and
most importantly retrieve wholly intact and viable CTCs from patient whole
blood. Benefiting a broad range of application areas including molecule
analysis, cancer diagnostics and cancer treatment decisions, this revolutionary
instrument also paves the way for personalised cancer medication for patients.
Speaking of this success, Andrew Lovatt, the CEO of
Dolomite, says, “We are excited to be working with an innovative company like
Clearbridge BioMedics. The collaboration is an excellent example of how
Dolomite is able to help start-up companies productize science. By combining
the cutting edge scientific research of Clearbridge BioMedics and National
University of Singapore with the proven track record in product development of
Dolomite, both companies have leveraged their expertise to gain early traction
in the novel field of automated capture of viable CTCs. We are looking forward
to extending our partnership beyond research tools and into the clinical
diagnostic domain.”
“We see microfluidics playing an increasing key role in many
Companion Diagnostics and In-Vitro Diagnostics devices. Dolomite has
demonstrated that they are indeed a leader in this field, and we look forward
to developing our future platform devices and systems together”, commented
Johnson Chen, Managing Director of Clearbridge BioMedics.
For further information on Dolomites instrument development
solutions as well as the complete portfolio of microfluidic products including
chips, connectors/ interconnects, pumps, valves and custom devices please visit
www.dolomite-microfluidics.com.
